MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday

MoonLake Immunotherapeutics (NASDAQ:MLTX) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.09). On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

MoonLake Immunotherapeutics Trading Up 1.5 %

NASDAQ MLTX opened at $40.30 on Wednesday. The firm’s fifty day simple moving average is $46.24 and its two-hundred day simple moving average is $48.89. MoonLake Immunotherapeutics has a 12-month low of $37.55 and a 12-month high of $58.26. The firm has a market capitalization of $2.58 billion, a P/E ratio of -31.24 and a beta of 1.28.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. The Goldman Sachs Group lowered their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Needham & Company LLC lifted their price objective on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Finally, Wedbush reiterated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $83.20.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.